Amniotics

Board of Directors

Peter Buhl Jensen - Chairman of the Board since 2021

Peter Buhl Jensen

Chairman of the Board since 2021

Peter Buhl Jensen (born 1955) is MD specialist in internal medicine and has a DMSc. Peter Buhl Jensen has a strong combination of commercial experience and medical expertise, especially in oncology, and has written over 120 scientific articles. Peter Buhl Jensen is the founder of TopoTarget A/S, Allarity Therapeutics (formerly Oncology Venture) and Medical Prognosis Institute A/S, as well as several successful ventures in the Life Science sector. Peter Buhl Jensen backed TopoTarget’s IPO in 2005 and secured EMA and FDA approval of the company’s first product, Savene©/Totect©. Peter Buhl Jensen was also involved in the IPO of Allarity Therapeutics and the Medical Prognosis Institute. In addition, Peter Buhl Jensen is behind the development of the drug Belinostat, which was approved by the FDA in the summer of 2014. Peter Buhl Jensen has leadership experience from TopoTarget, where he led approximately 140 employees, as well as from Aalborg University Hospital where he was a senior consultant at the Department of Oncology and led approximately 280 employees. Furthermore, Peter Buhl Jensen is an adjunct professor of clinical oncology at the University of Copenhagen and has been a consultant physician and led LEMO (Laboratory of Experimental Medical Oncology) at Rigshospitalet University Hospital in Copenhagen.

Other ongoing assignments: Board member of Cobis A/S, Symbion A/S and Symbion Foundation. CEO of Symbion A/S. Member of the Management Board (Executive Board) of Buhl Krone Holding ApS.

Holdings in the company: 0 Shares

Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.

Anders Månsson - Board member since 2017

Anders Månsson

Board member since 2017

Anders Månsson (born 1967) holds a bachelor’s degree in business and economics from Lund University and an MBA from Business School Lausanne. Anders Månsson has more than 25 years of experience in the pharmaceutical industry and life sciences, as well as experience from several leading positions within multinational pharmaceutical companies both in Sweden and abroad, primarily in sales, marketing and business development, which included work on distribution and licensing agreements, divestments and acquisitions in the billion class. In recent years, Anders Månsson was the previous CEO of Amniotics AB, he has been Industrial Advisor in Life Science to Ratos AB and Vice President of LEO Pharma. Anders Månsson is currently CEO of RhoVac AB, a biotechnology company active in immuno-oncology.

Other ongoing assignments: Chairman of the Board of EQL Pharma AB. Board member and CEO of Anders Månsson Business Development AB. CEO of RhoVac AB and RhoVac ApS.

Holdings in the company: 199 000 Shares, 247 warrants series 2017/2021 and 162 warrants series 2018/2021

Position of dependency: Dependent in relation to the company and its management, but independent in relation to major shareholders.

Christer Fåhraeus - Founding member. Board member since 2015, former Chairman of the Board

Christer Fåhraeus

Founding member. Board member since 2015, former Chairman of the Board

Christer Fåhraeus (born 1965) holds a master’s degree in medical physics, a PhD in neurophysiology, a bachelor’s degree in medicine, a bachelor’s degree in mathematics and an honorary doctorate in technology from Lund University. Christer Fåhraeus has many years of board and chairman experience from listed and unlisted companies in the Life Science and tech sector, and is the founder of Agellis Group AB, Anoto Group AB, Precise Biometrics AB, CellaVision AB, EQL Pharma AB and FlatFrog Laboratories AB.

Other ongoing assignments: Chairman of the Board of ApoEco Sverige AB, BionamicAB, Bizz Bike Sweden AB, Respiratorius AB (publ) and Uman Sense AB. Board member of CellaVision AB, EQL Pharma AB, Eql Pharma Int AB, FlatFrog Laboratories AB, Fåhraeus Institute AB,Fårö Capital AB, Gasporox AB (publ), IntuiCell AB, Reccan Diagnostics AB, ScandiDos AB, Serstech AB, Serstech Förvaltning AB, Smältan Invest AB, Theope Seed Capital AB and Wranne Fåhraeus Design AB. Deputy Board member of Bergdalsten Kemi AB and CJ Scandinavian Seaview Consulting AB. CEO of EQL Pharma AB.

Holdings in the company: 1 395 000 Shares

Position of dependency: Independent in relation to the company and its management, but not in relation to major shareholders.

Christopher Bravery - Board member since 2021

Christopher Bravery

Board member since 2021

Christopher Bravery (born 1967) holds a PhD in immunology from Imperial College, London, and a bachelor’s degree in biochemistry. Christopher Bravery is a researcher with over 20 years of experience in the pharmaceutical industry and with a primary focus on advanced therapies including Advanced Therapy Medicinal Products (ATMP),cells, gene and tissue products and other products for regenerative medicine. Christopher Bravery has deep knowledge of preclinical regulatory science from work in both the biotechnology industry and work at the regulatory authority. Christopher Bravery also has a good understanding of clinical trials in the EU, as well as licensing and post-licensing requirements from experience as a reviewer at the Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency. During his time at the MHRA, Christopher Bravery was involved in the national implementation of the Regulation of the European Parliament and of the Council on advanced therapy medicinal products and has also been active on the European Medicines Agency’s Committee on Medicinal Products for Human Use’s Working Group on Cell Products.

Other ongoing assignments: CEO of Consulting on Advanced Biologicals Ltd.

Holdings in the company: 0 Shares

Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.

Fredrik Tiberg - Board member since 2021

Fredrik Tiberg

Board member since 2021

Fredrik Tiberg (born 1963) holds a MSc in Chemical Engineering from Lund University of Technology and a PhD in Physical Chemistry at Lund University. Fredrik Tiberg has extensive experience from the biotechnology and pharmaceutical industry. He has since 2003 served as President & CEO, Head of R&D at Camurus AB, where he is also a member of the board. Previous roles include CEO of Heptahelix AB, adjunct professor of surface chemistry at Lund University and visiting professor of physical and theoretical chemistry at the University of Oxford.
Fredrik has more than 110 publications in peer-reviewed scientific journals, is named inventor on more than 400 patents and patent applications and is a member of the Royal Swedish Academy of Engineering Sciences (IVA).

Other ongoing assignments: Board member of Camurus AB, Camurus Development AB, and Camurus Lipid Research Foundation. President and CEO of Camurus AB.

Holdings in the company: 11 500 Shares

Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.

Ingrid Atteryd Heiman - Board member since 2021

Ingrid Atteryd Heiman

Board member since 2021

Ingrid Atteryd Heiman (born 1958) holds a BA in financing and industrial marketing from Lund University and an MBA in International Business from Uppsala University. She has more than 15 years of experience in the self-care market as CEO and Chairman of the trade association, Svensk Egenvård and its European counterpart as well as CEO and Chairman of the Board of Ellen AB. Ingrid Atteryd Heiman also has experience in management and board work with a focus on food, pharmaceuticals, biomedicine, Life Science and women’s health as well as experience as a board member and chairman of the board from several listed Life Science companies. Ingrid Atteryd Heiman has successfully proven her ability to strategize business development and drive profit and growth, and through her experience in management consulting in Booz (now part of PwC), has been involved in efficiency optimization, strategy development, mergers and acquisitions and IPOs. In addition, ms. Atteryd Heiman has experience in international business including business development in Europe, US and Asia, as well as work with lobbying in the European Parliament.

Other ongoing assignments: Chairman of the Board of Doxa AB and Doxa Dental AB. Board member of Dignitana AB (publ), Pharmiva AB (publ), Redwood Pharma AB (publ), CarpoNovum AB, and Ilama AB.

Holdings in the company: 0 Shares

Position of dependency: Independent in relation to the company and its management, and in relation to major shareholders.

Marcus Larsson - Founding member. Board member since 2015

Marcus Larsson

Founding member. Board member since 2015

Marcus Larsson (born 1973) is a licensed physician with a degree from Lund University and a specialist in pediatrics and clinical practice at neonatal clinic, Skåne University Hospital. Marcus Larsson has a PhD in clinical physiology with a special focus on the surface structure and function of the lung and is one of the founders of Amniotics. Marcus Larsson has over 20 years of research experience in physiology and biophysical chemistry and is co-inventing several patents in the field of pharmaceuticals and biotechnology. Marcus Larsson is also Chairman of the Board of Camurus Lipid Research Foundation.

Other ongoing assignments: Board member of Deflexum AB.

Holdings in the company: 1 556 000 Shares

Position of dependency: Dependent in relation to the company and its management, and major shareholders.